I daresay, any deal with Luminex will be overwhelming in PR and underwhelming in revenue, similar to deals with Banglabs, Merck, Ebioscience and Affymetrix.
All evidence points to the fact that this technology is not disrupting at all.
getting a drug through to a phase 3 clinical trial would be quicker in it's progress
It may have a niche but nothing to justify the present market cap.
I daresay, any deal with Luminex will be overwhelming in PR and...
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $50.57M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.3¢ | 2.1¢ | $38.09K | 1.731M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1505316 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 676543 | 1 |
View Market Depth
| Last trade - 15.57pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.2¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.3¢ | 2.2¢ | 764931 | ||
| Last updated 15.55pm 03/05/2024 ? | |||||
| ADO (ASX) Chart |